At Mass General Brigham Cancer Institute in Boston, researchers have developed a blood test so sensitive it can spot lingering cancer cells seven months before doctors see them on scans—potentially transforming how thousands of head and neck cancer patients are treated after surgery.
The test, called HPV-DeepSeek, detects tiny fragments of viral DNA circulating in the bloodstream from HPV-associated head and neck cancers. These cancers are caused when human papillomavirus inserts its genetic code into cells and drives them to form tumors. As tumor cells grow and die naturally, they shed microscopic pieces of HPV DNA into the blood—a signature that HPV-DeepSeek can now catch with unprecedented precision.
The significance lies in timing. Today, doctors use broad clinical risk factors to decide whether patients need chemotherapy or radiation after surgery, a one-size-fits-most approach that leaves many guessing. Some patients receive treatments they didn't need, enduring harsh side effects for no benefit. Others receive less treatment than necessary and later watch their cancer return. "We currently rely on very general clinical risk factors to determine which patients need more treatment and which patients do not," said Daniel Faden, MD, Director of the Head and Neck Cancer Genomics and Liquid Biopsy Program at Mass General Brigham. "That means some patients receive more treatment than they actually need, resulting in more side effects of treatment, while others receive less treatment than they should—and later have their cancer come back."
The study, called Clear-HPVca, followed 103 patients with newly diagnosed HPV-associated head and neck cancer scheduled for surgery between August 2020 and March 2024. Researchers collected and analyzed 560 blood samples before surgery, immediately after, and during ongoing surveillance over more than two years. At diagnosis, HPV-DeepSeek detected circulating tumor DNA in 98.1% of patients—nearly universal sensitivity. The key measure came after surgery: 23% of patients still had detectable tumor DNA, a sign of residual disease.
The results were stark. Among patients with positive HPV-DeepSeek tests after surgery, only 60% were disease-free two years later. Among those with negative tests, 100% remained cancer-free. For overall survival, patients with detectable tumor DNA saw 73% survival rates compared with 98% for those testing negative. Compared to existing HPV blood tests, HPV-DeepSeek was substantially more sensitive and could detect recurrence approximately seven months earlier—nearly double the lead time of current alternatives, and in some cases extending up to 17.5 months.
The implications are profound. Early detection of recurrence could allow doctors to intervene before cancer spreads, while accurate identification of patients with no residual disease could spare them unnecessary toxicity. "If we can accurately identify residual disease at the molecular level, we may eventually be able to make treatment decisions based on the biology of an individual patient's cancer rather than broad clinical categories," Faden said.
The study, published in Science Translational Medicine, had limitations—it was observational and conducted at a single health system with relatively small numbers of recurrences and deaths. But these results have prompted the research team to launch larger, multi-site clinical trials to test whether HPV-DeepSeek results can actually guide post-surgery treatment decisions in real time, moving personalized cancer care from possibility into practice.